A panel at the 2025 MedTech Conference, which took place in San Diego in the US state of California from 5 to 8 October, emphasised that although women account for more than half of the global population, “women’s health” is still considered by some to be a niche market.
But while many barriers remain, growing demand for more gender-specific medical innovation means that medtech devices related to women’s health are increasingly drawing investor interest.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
GlobalData analyses shows that the number of medical devices receiving approval for indications associated with women’s health is indeed growing (see Figure 1). These newly approved devices are associated indications such as female cancers, urinary incontinence, pelvic floor disorders, female infertility, systemic lupus erythematosus, iron deficient anaemia, pregnancy-related complications and postpartum haemorrhage.Â
Figure 1: Number of medical devices approved per year associated with indications predominantly impacting women. Credit: GlobalData.
Among women’s health devices approved between 2020 and 2025, there have been some notable success stories.
The , first developed by Alydia Health Inc and sold by Organon & Co, received US Food and Drugs Administration (FDA) approval in 2020 for treating postpartum haemorrhage, a life-threatening obstetric emergency that requires rapid medical intervention.
grew 40% in 2024. Between 2023 and 2025, Organon & Co expanded sales to new geographies such as Canada and Australia. Â
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe Teal Wand is a self-collection device highlighted by the Innovator Showcase at the 2025 MedTech Conference. It allows women to comfortably, conveniently and privately screen for cervical cancer at home. in the same year and has been used by 600 women since its launch.
The platform by EDAP TMS SA is a robotic, high-intensity focused ultrasound system designed for minimally invasive tissue ablation. Already approved for prostate disease, Focal One for treating deep infiltrating endometriosis. EDAP TMS SA has invested in several clinical trials aimed at expanding focal therapy to new clinical indications and in March 2025 Focal One received CE Mark certification in Europe for endometriosis.
While many challenges remain, these advances signal a meaningful shift toward recognising and investing in innovations that address women’s unique health needs. Continued collaboration among researchers, regulators, investors and patient communities will be essential to sustain momentum and translate potential into widespread impact.
